Supplementary Material for Pfizer Oncology’s Thoracic Cancer Pipeline – April 2025
Year: 2025
Type: supplementary-materials
Abstract: Congress materials may include information for investigational products or for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Regulatory approval of investigational products or uses is dependent on the completion of the study programs and review by regulatory authorities. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information. The clinical trial information is available at www.clinicaltrials.gov. This information is current as of April 1, 2025.
Source: Figshare
Authors: Becker, Mauricio, Garas, Sam
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W6907932858
Cites:
Cited by:
Related to: